Abeona Announces Equity Financing; Aquinox to Provide Update on Phase 2 LEADERSHIP Trial in BPS/IC Print
By Josh Gee   
Tuesday, 28 July 2015 20:38
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 28, 2015.
  
Abeona Therapeutics, Inc. (NASDAQ: ABEO), announced it had entered into a definitive purchase agreements with two leading healthcare institutional investors, Soros Fund Management and Perceptive Life Science Fund, and two Members of the Board of Directors, to raise $8.5 million in a direct placement of registered common stock. The financing is comprised of 1,547,273 shares of common stock at a price of $5.50 per share, which represents a premium to yesterday's closing price of $5.46. Abeona Therapeutics plans to use the proceeds of the financing for the development of its proprietary rare disease programs, working capital and general corporate purposes.
  
"We are encouraged that current institutional investors and members of the Board of Directors are both pleased with our progress, and supportive financially of our plans going forward," stated Steven H. Rouhandeh, Executive Chairman. "As we continue to build into a leading rare disease company, we have the products, technology platforms, team and financial resources to meet and exceed our development milestones."
   
The securities described above are being offered pursuant to a registration statement (File No. 333-205128) which became effective on July 23, 2015. When filed with the Securities and Exchange Commission, copies of the final prospectus for the offering can be obtained at the SEC's website at http://www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
  
  
  
  
=================================
  
  
  
  
Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and
developing targeted therapeutics in disease areas of inflammation and

Error. Page cannot be displayed. Please contact your service provider for more details. (7)

immuno-oncology, will provide an update on results from secondary endpoints from its recently completed Phase 2 LEADERSHIP randomized clinical trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). Aquinox will also provide a general business update and
report second quarter 2015 financial results on Thursday, August 6th, 2015 after close of U.S. financial markets.
   
Aquinox will host a conference call and live webcast on Thursday, August 6th, 2015 at 4:45 PM (ET) / 1:45 PM (PT). Presentation slides will accompany the webcast and will be posted to the Aquinox website following completion of the call.
   
Conference Call and Webcast Details:  
Date: Thursday, August 6th, 2015 Time: 4:45 PM (ET) / 1:45 PM (PT).
Toll-free: (866) 357-7878
International: (315) 625-3088
Conference ID: 96372657
Webcast URL: http://edge.media-server.com/m/p/4b67r6k9
  
  
  
  
   
Also Tuesday:
  
  
  
  
   
Cambrex Corporation (NYSE:CBM) announced that second quarter 2015 financial results will be released on Thursday, July 30, 2015 before the market opens.
   
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, August 10, 2015 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 2015 financial results and product updates. 
   
Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced positive topline interim results from its Phase 2a study designed to determine the pharmacokinetics (PK), pharmacodynamics (PD) and safety and tolerability of its MicroCor transdermal system for the rapid delivery of a treatment for osteoporosis.
   
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Aug. 4th, at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update.
   
Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the Company will be participating in two upcoming investor conferences.
   
Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the second quarter of 2015 after market close on Tuesday, August 11, 2015. 
   
Kindred Healthcare, Inc. (NYSE:KND) today announced that it will provide an online, real-time webcast of its conference call covering second quarter 2015 operating results on Thursday, August 6, 2015. 
   
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, reported results for the fiscal 2015 fourth quarter and fiscal year ended May 31, 2015.
   
Medical Marijuana, Inc. (OTC Pink:MJNA) announced in October that it filed a $100 million lawsuit against multiple companies that published false allegations about Medical Marijuana, Inc. its portfolio companies and CBD hemp oil brands. 
   
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and six months ended June 30, 2015, after the market close on Monday, August 3, 2015.
   
Natural Health Trends Corp. (Nasdaq:NHTC), a leading direct selling company that markets premium quality personal care, wellness and "quality of life" products under the NHT Global brand, today announced continued growth for the quarter and six month periods ended June 30, 2015.
   
Novadaq Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, today announced financial results for its second quarter ended June 30, 2015.
   
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its anti-RSPO3 antibody (OMP-131R10) Phase 1a/1b clinical trial.
   
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today announced that the company will report second quarter 2015 financial results and provide a business update on Tuesday, August 4, 2015.
   
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative ways to target and treat cancer, announced today that the U.S. Food and Drug Administration (FDA) has designated Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma. Azedra is currently being evaluated in a pivotal Phase 2b trial, which is being conducted under a Special Protocol Assessment Agreement (SPA), and has received Orphan Drug and Fast Track designations from the FDA.
  
Spine Pain Management, Inc. (OTCQB:SPIN), a technology-driven, medical service, device and healthcare solution company servicing the multi-billion dollar spine injury sector, is pleased to announce that its Quad Video HALO (QVH), a revolutionary video transparency accessory for medical fluoroscopy devices, has been issued a "Final Patent" allowing all claims, by the U.S. Patent and Trademark Office for Patent Application No. 9,084,577 B2.
   
Nymox’s (NASDAQ:NYMX) July 27th webcast of news and discussion by experts of the Company's new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_investor_webcast_7_15/player_vod.html. 
   
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 second quarter ended June 30, 2015 on Tuesday, August 4, 2015 before the open of the U.S. financial markets.
   
Tandem Diabetes Care®, Inc. (NASDAQ:TNDM), a medical device company and manufacturer of the t:slim® and t:flex™ Insulin Pumps, today announced that Kim Blickenstaff, president and CEO, will present a company update at the 2015 Wedbush PacGrow Healthcare Conference in New York, NY. 
   
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2015.
   
Vapir Enterprises, Inc. (OTCQB:VAPI), a developer and manufacturer of revolutionary, state-of-the-art, and user friendly medical-grade vaporization devices, showcased its newest device at the industry-leading CHAMPS Las Vegas trade show in July.
 
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it intends to offer and sell 3,800,000 shares of its common stock in an underwritten public offering.



BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
  BMR:1